單株抗體合作與授權協議（2019-2026）

單株抗體交易的權威基準

單株抗體合作的驅動力來自成熟但不斷發展的生物製藥領域，其合約結構體現了成熟的開發流程和新一代抗體形式的持續創新。

本報告對超過 740 項單株抗體合作與許可協議進行了全面系統的分析，清楚地展示了整個市場夥伴關係的設計、談判和執行方式，並提供了基於證據的清晰視角。

清楚了解市場標準

本報告對單株抗體領域的合約實際是如何建構的提供了精確的理解。

• 類似交易的可靠基準
• 對相關合約中的預付款、里程碑付款和特許權使用費結構進行詳細分析
• 定義切合實際的市場參數
• 清晰洞察基於抗體類型、研發階段和合作夥伴情況的合約條款差異。
• 支持基於證據的評估和合約結構確定。
• 讓內部討論基於實際交易數據，而不是僅基於假設。
• 了解主要公司的交易方式
• 在競爭激烈、創新主導的生物製劑市場中，可視化合作夥伴的行為模式和迭代合約結構。
• 完全透明地了解合約的結構和執行情況
• 本報告超越了表面的合約數據，提供了對底層合約文件的訪問，以便詳細了解實際協議是如何構建的。

這包括以下內容：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和付款條款
• 關鍵合約條款和保護措施
• 這種透明度對於理解單株抗體合作中價值、風險和控制權的分配至關重要。在涉及差異化生物製藥和不斷發展的治療策略的領域，其重要性更為顯著。
• 專為實際業務發展和策略應用而設計。

本報告廣泛用於以下用途：

• 生物製藥領域的交易結構與基準分析
• 在清晰的市場環境下準備談判
• 評估許可和合作開發機會
• 利用可靠且可解釋的數據支持內部策略規劃

本報告內容：

• 超過740項與單株抗體相關的合作和授權協議
• 財務條款，包括預付款、里程碑付款和特許權使用費（如已揭露）。
• 可全文搜尋的合約目錄（依公司、治療領域及抗體類型）
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 合約趨勢、重大交易和活躍合約方分析。
• 用於單株抗體交易的可靠依證
• 本報告結合了全面的合約資料覆蓋和詳細的合約層面分析，為在單株抗體領域建立、談判和評估夥伴關係提供了可靠的、依證證據的參考。

目錄

執行摘要

第1章：引言

第2章：單株抗體的交易趨勢

• 過去幾年在單株抗體的合作
• 單株抗體領域最活躍的交易方
• 單株抗體合約：依合約類型
• 單株抗體合約：按治療領域分類
• 單株抗體合約：按行業分類
• 單株抗體合約條款
  • 標題金額
  • 預付款
  • 里程碑付款
  • 權利金費率

第3章 主要單株抗體合約

• 按合約價值排名的單株抗體合約

第4章：單株抗體領域最活躍的締約方

• 單株抗體領域最活躍的締約方
• 單株抗體領域最活躍的簽約方的公司簡介

第5章：單株抗體合約目錄

• 單株抗體合約目錄

第6章 單株抗體合約：依技術類型分類

• 合約目錄
• 合約目錄：單株抗體合約（依公司名稱 A-Z 排序）
• 合約目錄：單株抗體合約（依合約類型分類）
• 合約目錄：按治療領域分類的單株抗體合約
• 合約類型的定義
• 關於 Biopharma Research Ltd.
• 關於當前合作夥伴關係
• 關於現行協議
• Current Partnering 最新報告列表

The definitive benchmark for monoclonal antibody dealmaking

Monoclonal antibody partnering is driven by a well-established yet continuously evolving class of biologic therapies, with deal structures reflecting both mature development pathways and ongoing innovation in next-generation antibody formats.

This report provides a comprehensive and structured analysis of 740+ monoclonal antibody collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how monoclonal antibody deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by development stage, antibody type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a competitive and innovation-driven biologics landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within monoclonal antibody partnerships, particularly in areas involving differentiated biologics and evolving therapeutic strategies.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark biologics transactions
• Prepare for negotiations with well-defined market context
• Evaluate licensing and co-development opportunities
• Support internal strategy with robust, defensible data
• What's included
• 740+ monoclonal antibody collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and antibody type)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for monoclonal antibody dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how monoclonal antibody partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in monoclonal antibody dealmaking

• 2.1. Introduction
• 2.2. Monoclonal antibody deals over the years
• 2.3. Most active monoclonal antibody dealmakers
• 2.4. Monoclonal antibody deals by deal type
• 2.5. Monoclonal antibody deals by therapy area
• 2.6. Monoclonal antibody deals by industry sector
• 2.7. Deal terms for monoclonal antibody deals
  • 2.7.1 Monoclonal antibody deals headline values
  • 2.7.2 Monoclonal antibody deal upfront payments
  • 2.7.3 Monoclonal antibody deal milestone payments
  • 2.7.4 Monoclonal antibody royalty rates

Chapter 3 - Leading monoclonal antibody deals

• 3.1. Introduction
• 3.2. Top monoclonal antibody deals by value

Chapter 4 - Most active monoclonal antibody dealmakers

• 4.1. Introduction
• 4.2. Most active monoclonal antibody dealmakers
• 4.3. Most active monoclonal antibody deals company profiles

Chapter 5 - Monoclonal antibody contracts dealmaking directory

• 5.1. Introduction
• 5.2. Monoclonal antibody contracts dealmaking directory

Chapter 6 - Monoclonal antibody dealmaking by technology type

• Deal directory
• Deal directory - Monoclonal antibody deals by company A-Z
• Deal directory - Monoclonal antibody deals by deal type
• Deal directory - Monoclonal antibody deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Monoclonal antibody deals since 2019
• Figure 2: Active monoclonal antibody dealmaking activity since 2019
• Figure 3: Monoclonal antibody deals by deal type since 2019
• Figure 4: Monoclonal antibody deals by therapy area since 2019
• Figure 5: Monoclonal antibody deals by industry sector since 2019
• Figure 6: Monoclonal antibody deals with a headline value
• Figure 7: Monoclonal antibody deals with an upfront value
• Figure 8: Monoclonal antibody deals with a milestone value
• Figure 9: Monoclonal antibody deals with a royalty rate value
• Figure 10: Top monoclonal antibody deals by value since 2019
• Figure 11: Most active monoclonal antibody dealmakers since 2019
• Figure 12: Monoclonal antibody deals by technology type since 2019